Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 379-384

  Du Bois, A ^a   Luck H J ^b   Buser, K ^b   Meerpohl, H G ^b   Sessa, C ^c   Klaassen, U ^b   Meden, H ^d   Bochtler, H ^e   Diergarten, K ^e  

^a Frauenkl St Vincentius K   (Germany)

^b Department of Gynecologic Oncology ^*

^c OSPEDALE SAN GIOVANNI   (Switzerland)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

ovarian neoplasms; paclitaxel; platinum resistance; recurrence; salvage therapy

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031106191     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89009-0     Document Type: Article

References (17)

1. Estève J, Kricker A, Ferlay J, Parkin DM. in collaboration with the Steering Committee of the European Network of Cancer Registries. Facts and Figures of Cancer in the European Community. 1993;International Agency or Research on Cancer, Lyon.
2. Ovarian cancer: screening, treatment and follow-up. National Institutes of Health Consensus Development Conference Statement. Gynecol Oncol. 55:1994;S4-S14.
3. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol. 10:1992;513-514.
4. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol. 55:1994;S143-S150.
5. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
6. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:1990;207-211.
7. Conte PF, Gadducci A, Fioretti P, Bruzzone M, Brunetti I, Ragni N. Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma. Eur J Gynaecol Oncol. 15:1994;313-318.
8. Seewaldt VL, Greer BE, Cain JM, et al. Paclitaxel (taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol. 170:1994;1666-1671.
9. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol. 11:1993;2405-2410.
10. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 12:1994;1748-1753.
11. Sarosy G, Stone DA, Rothenberg M, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol. 10:1992;1165-1170.
12. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med. 111:1989;273-279.
13. Ovarian cancer: screening, treatment and follow-up. National Institutes of Health Consensus Development Conference Statement. Gynecol Oncol. 55:1994;S11.
14. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 12:1994;2654-2666.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
16. Gore ME, Levy V, Rustin G, et al. Paclitaxel (taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer. 72:1995;1016-1019.
17. Rowinsky RK, Mackey MK, Goodman SN. Meta analysis of paclitaxel (P) dose-response and dose-intensity (DI) in recurrent or refractory ovarian cancer (OC). Proc Am Soc Clin Oncol. 15:1996;288. (abstract 770).